FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs. Its lead product candidate, Roxadustat, is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity; it has completed Phase III clinical development for anemia in chronic kidney disease in China, Europe, Japan, and other countries, and is in Phase III development for anemia associated with myelodysplastic syndromes. The pipeline also includes FG-3165 and FG-3175, an anti-GAL-9 antibody for the treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB, and was incorporated in 1993 with headquarters in San Francisco, California.